{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T05:02:51Z","timestamp":1772773371511,"version":"3.50.1"},"reference-count":105,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.intimp.2024.113883","type":"journal-article","created":{"date-parts":[[2024,12,22]],"date-time":"2024-12-22T10:00:32Z","timestamp":1734861632000},"page":"113883","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Where are we in targeting hypoxia-induced pathways in inflammatory arthritis? Current understanding, insights, and future directions"],"prefix":"10.1016","volume":"146","author":[{"given":"Lisa","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2024.113883_b0005","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.freeradbiomed.2018.03.042","article-title":"Hypoxia, oxidative stress and inflammation","volume":"125","author":"McGarry","year":"2018","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.intimp.2024.113883_b0010","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.berh.2012.03.001","article-title":"Advances in the treatment of inflammatory arthritis","volume":"26","author":"Pisetsky","year":"2012","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"10.1016\/j.intimp.2024.113883_b0015","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/art.20018","article-title":"Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors","volume":"50","author":"Nielen","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2024.113883_b0020","first-page":"S26","article-title":"The immunology of ankylosing spondylitis and rheumatoid arthritis: a tale of similarities and dissimilarities","volume":"27","author":"Inman","year":"2009","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.intimp.2024.113883_b0025","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s12969-021-00629-8","article-title":"Juvenile idiopathic arthritis: from aetiopathogenesis to therapeutic approaches","volume":"19","author":"Zaripova","year":"2021","journal-title":"Pediatr. Rheumatol. Online J."},{"key":"10.1016\/j.intimp.2024.113883_b0030","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12041630","article-title":"Past, Present and (Foreseeable) Future of Biological Anti-TNF Alpha Therapy","volume":"12","author":"Leone","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.intimp.2024.113883_b0035","first-page":"1135","article-title":"Difficult-to-treat rheumatoid arthritis: an area of unmet clinical need","volume":"57","author":"de Hair","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.intimp.2024.113883_b0040","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s10787-022-00974-4","article-title":"Elucidating the role of hypoxia-inducible factor in rheumatoid arthritis","volume":"30","author":"Sabi","year":"2022","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.intimp.2024.113883_b0045","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/art.1780130606","article-title":"Oxygen tension in synovial fluids","volume":"13","author":"Lund-Olesen","year":"1970","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2024.113883_b0050","doi-asserted-by":"crossref","first-page":"338","DOI":"10.5114\/ceji.2023.134217","article-title":"The pathogenesis and regulatory role of HIF-1 in rheumatoid arthritis","volume":"48","author":"Li","year":"2023","journal-title":"Cent Eur J Immunol"},{"key":"10.1016\/j.intimp.2024.113883_b0055","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrrheum.2011.205","article-title":"Hypoxia\u2013a key regulator of angiogenesis and inflammation in rheumatoid arthritis","volume":"8","author":"Konisti","year":"2012","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.intimp.2024.113883_b0060","first-page":"945","article-title":"Hypoxia inducible factor-1-alpha (HIF-1alpha) is related to both angiogenesis and inflammation in rheumatoid arthritis","volume":"27","author":"Brouwer","year":"2009","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.intimp.2024.113883_b0065","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.cell.2012.01.021","article-title":"Hypoxia-inducible factors in physiology and medicine","volume":"148","author":"Semenza","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2024.113883_b0070","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/s41423-024-01183-5","article-title":"HIF-1\u03b1 and MIF enhance neutrophil-driven type 3 immunity and chondrogenesis in a murine spondyloarthritis model","volume":"21","author":"Nakamura","year":"2024","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.intimp.2024.113883_b0075","article-title":"Emerging role of hypoxia-inducible factor-1\u03b1 in inflammatory autoimmune diseases: A comprehensive review","volume":"13","author":"Tang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2024.113883_b0080","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/eji.201545784","article-title":"Hypoxia-inducible factor-1\u03b1 perpetuates synovial fibroblast interactions with T cells and B cells in rheumatoid arthritis","volume":"46","author":"Hu","year":"2016","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.intimp.2024.113883_b0085","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1302\/2046-3758.117.BJR-2021-0594.R1","article-title":"Immunomodulatory role of T helper cells in rheumatoid arthritis: a comprehensive research review","volume":"11","author":"Luo","year":"2022","journal-title":"Bone Joint Res"},{"key":"10.1016\/j.intimp.2024.113883_b0090","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1136\/annrheumdis-2014-206921","article-title":"Expression of chemokines CXCL4 and CXCL7 by synovial macrophages defines an early stage of rheumatoid arthritis","volume":"75","author":"Yeo","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2024.113883_b0095","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1136\/ard.58.5.297","article-title":"Macrophage inflammatory protein 1 alpha expression by synovial fluid neutrophils in rheumatoid arthritis","volume":"58","author":"Hatano","year":"1999","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2024.113883_b0100","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.139032","article-title":"Pathogenic, glycolytic PD-1+ B cells accumulate in the hypoxic RA joint","volume":"5","author":"Floudas","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.intimp.2024.113883_b0105","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/s41590-023-01527-9","article-title":"Drivers of heterogeneity in synovial fibroblasts in rheumatoid arthritis","volume":"24","author":"Smith","year":"2023","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.intimp.2024.113883_b0110","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1002\/art.22493","article-title":"LIGHT up-regulated on B lymphocytes and monocytes in rheumatoid arthritis mediates cellular adhesion and metalloproteinase production by synoviocytes","volume":"56","author":"Kang","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2024.113883_b0115","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.clim.2004.12.009","article-title":"The fibroblast-like synovial cell in rheumatoid arthritis: a key player in inflammation and joint destruction","volume":"115","author":"Mor","year":"2005","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.intimp.2024.113883_b0120","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.3389\/fimmu.2019.01395","article-title":"Regulation of Immune Responses and Chronic Inflammation by Fibroblast-Like Synoviocytes","volume":"10","author":"Yoshitomi","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2024.113883_b0125","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/HYPERTENSIONAHA.117.10271","article-title":"Mechanisms of VEGF (Vascular Endothelial Growth Factor) Inhibitor-Associated Hypertension and Vascular Disease","volume":"71","author":"Pandey","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.intimp.2024.113883_b0130","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/j.bmc.2007.01.011","article-title":"Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs","volume":"15","author":"Verma","year":"2007","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.intimp.2024.113883_b0135","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.coph.2005.06.005","article-title":"Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength","volume":"5","author":"Kostenuik","year":"2005","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.intimp.2024.113883_b0140","first-page":"1072","article-title":"Decrease in articular hypoxia and synovial blood flow at early time points following infliximab and etanercept treatment in rheumatoid arthritis","volume":"34","author":"Fisher","year":"2016","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.intimp.2024.113883_b0145","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1002\/art.1780341206","article-title":"A comparative study by morphometry of the microvasculature in normal and rheumatoid synovium","volume":"34","author":"Stevens","year":"1991","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2024.113883_b0150","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/art.27287","article-title":"Angiogenesis and blood vessel stability in inflammatory arthritis","volume":"62","author":"Kennedy","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2024.113883_b0155","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1136\/ard.59.2.125","article-title":"Angiotensin converting enzyme in human synovium: increased stromal [(125)I]351A binding in rheumatoid arthritis","volume":"59","author":"Walsh","year":"2000","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2024.113883_b0160","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.3389\/fimmu.2020.01668","article-title":"Hypoxia-Inducible Factor Is Critical for Pathogenesis and Regulation of Immune Cell Functions in Rheumatoid Arthritis","volume":"11","author":"Guo","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2024.113883_b0165","doi-asserted-by":"crossref","first-page":"10212","DOI":"10.1093\/nar\/gkz766","article-title":"HIF-transcribed p53 chaperones HIF-1\u03b1","volume":"47","author":"Madan","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.intimp.2024.113883_b0170","doi-asserted-by":"crossref","first-page":"184","DOI":"10.3389\/fphar.2016.00184","article-title":"Hypoxia-Inducible Factor (HIF) as a Target for Novel Therapies in Rheumatoid Arthritis","volume":"7","author":"Hua","year":"2016","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.intimp.2024.113883_b0175","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1002\/art.34479","article-title":"Prolyl hydroxylase domain enzyme 2 is the major player in regulating hypoxic responses in rheumatoid arthritis","volume":"64","author":"Muz","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2024.113883_b0180","article-title":"Local Stabilization of Hypoxia-Inducible Factor-1\u03b1 Controls Intestinal Inflammation via Enhanced Gut Barrier Function and Immune Regulation","volume":"11","author":"Kim","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2024.113883_b0185","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1074\/jbc.270.3.1230","article-title":"Purification and characterization of hypoxia-inducible factor 1","volume":"270","author":"Wang","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.intimp.2024.113883_b0190","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1182\/blood-2013-05-500207","article-title":"Hypoxia-inducible factor 2\u03b1 regulates key neutrophil functions in humans, mice, and zebrafish","volume":"123","author":"Thompson","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2024.113883_b0195","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12929-016-0281-0","article-title":"Hypoxia and its implications in rheumatoid arthritis","volume":"23","author":"Qui\u00f1onez-Flores","year":"2016","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.intimp.2024.113883_b0200","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1172\/JCI57322","article-title":"Endothelial HIF-2\u03b1 regulates murine pathological angiogenesis and revascularization processes","volume":"122","author":"Skuli","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.intimp.2024.113883_b0205","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1016\/S0140-6736(23)01525-8","article-title":"Rheumatoid arthritis","volume":"402","author":"Di Matteo","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2024.113883_b0210","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1007\/s00296-009-0865-z","article-title":"Characterization of synovial tissue from arthritis patients: a proton magnetic resonance spectroscopic investigation","volume":"29","author":"Hitchon","year":"2009","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.intimp.2024.113883_b0215","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.molimm.2012.08.018","article-title":"Interleukin-17A promotes rheumatoid arthritis synoviocytes migration and invasion under hypoxia by increasing MMP2 and MMP9 expression through NF-\u03baB\/HIF-1\u03b1 pathway","volume":"53","author":"Li","year":"2013","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.intimp.2024.113883_b0220","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1093\/rheumatology\/ken086","article-title":"Role of hypoxia-inducible factor-1alpha in hypoxia-induced expressions of IL-8, MMP-1 and MMP-3 in rheumatoid fibroblast-like synoviocytes","volume":"47","author":"Ahn","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.intimp.2024.113883_b0225","first-page":"593","article-title":"Influence of hypoxia on the expression of matrix metalloproteinase-1, -3 and tissue inhibitor of metalloproteinase-1 in rheumatoid synovial fibroblasts","volume":"21","author":"Cha","year":"2003","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.intimp.2024.113883_b0230","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/art.11473","article-title":"The transcription factors hypoxia-inducible factor 1alpha and Ets-1 colocalize in the hypoxic synovium of inflamed joints in adjuvant-induced arthritis","volume":"50","author":"Peters","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2024.113883_b0235","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1006\/bbrc.2001.5927","article-title":"Hypoxia induces transcription factor ETS-1 via the activity of hypoxia-inducible factor-1","volume":"289","author":"Oikawa","year":"2001","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.intimp.2024.113883_b0240","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0109524","article-title":"Angiopoietin-like 4 is over-expressed in rheumatoid arthritis patients: association with pathological bone resorption","volume":"9","author":"Swales","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.intimp.2024.113883_b0245","article-title":"Energy Metabolism Disorder as a Contributing Factor of Rheumatoid Arthritis: A Comparative Proteomic and Metabolomic Study","volume":"10","author":"Yang","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.intimp.2024.113883_b0250","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1042\/BJ20111275","article-title":"The mitochondrial citrate carrier: a new player in inflammation","volume":"438","author":"Infantino","year":"2011","journal-title":"Biochem. J"},{"key":"10.1016\/j.intimp.2024.113883_b0255","article-title":"Complexity of enthesitis and new bone formation in ankylosing spondylitis: current understanding of the immunopathology and therapeutic approaches","author":"Kusuda","year":"2021","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.intimp.2024.113883_b0260","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00281-020-00833-w","article-title":"Aberrant antigen processing and presentation: Key pathogenic factors leading to immune activation in Ankylosing spondylitis","volume":"43","author":"Nakamura","year":"2021","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.intimp.2024.113883_b0265","doi-asserted-by":"crossref","unstructured":"Mauro D, Nakamura A, Haroon N, Ciccia F. The gut-enthesis axis and the pathogenesis of Spondyloarthritis. Semin Immunol 2022:101607. Doi: 10.1016\/j.smim.2022.101607.","DOI":"10.1016\/j.smim.2022.101607"},{"key":"10.1016\/j.intimp.2024.113883_b0270","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11926-021-00995-y","article-title":"Recent Updates in the Immunopathology of Type 3 Immunity-Mediated Enthesitis","volume":"23","author":"Nakamura","year":"2021","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.intimp.2024.113883_b0275","article-title":"Dysregulation of SAA1, TUBA8 and Monocytes Are Key Factors in Ankylosing Spondylitis With Femoral Head Necrosis","volume":"12","author":"Jiang","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2024.113883_b0280","doi-asserted-by":"crossref","unstructured":"Nakamura A, Zeng F, Nakamura S, Reid KT, Gracey E, Lim M, et al. Macrophage migration inhibitory factor drives pathology in a mouse model of spondyloarthritis and is associated with human disease. Sci Transl Med 2021;13:eabg1210. Doi: 10.1126\/scitranslmed.abg1210.","DOI":"10.1126\/scitranslmed.abg1210"},{"key":"10.1016\/j.intimp.2024.113883_b0285","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s11926-022-01081-7","article-title":"Deep Insight into the Role of MIF in Spondyloarthritis","volume":"24","author":"Wu","year":"2022","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.intimp.2024.113883_b0290","doi-asserted-by":"crossref","unstructured":"Orsini F, Crotti C, Cincinelli G, Di Taranto R, Amati A, Ferrito M, et al. Bone Involvement in Rheumatoid Arthritis and Spondyloartritis: An Updated Review. Biology (Basel) 2023;12. Doi: 10.3390\/biology12101320.","DOI":"10.20944\/preprints202309.0966.v1"},{"key":"10.1016\/j.intimp.2024.113883_b0295","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/intimm\/dxr111","article-title":"Dynamic regulation of Th17 differentiation by oxygen concentrations","volume":"24","author":"Ikejiri","year":"2012","journal-title":"Int. Immunol."},{"key":"10.1016\/j.intimp.2024.113883_b0300","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1084\/jem.20061308","article-title":"Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides","volume":"203","author":"Liang","year":"2006","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.intimp.2024.113883_b0305","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13075-018-1582-3","article-title":"IL-17A induces osteoblast differentiation by activating JAK2\/STAT3 in ankylosing spondylitis","volume":"20","author":"Jo","year":"2018","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.intimp.2024.113883_b0310","doi-asserted-by":"crossref","unstructured":"Ocampo D V, Gladman D. Psoriatic arthritis. F1000Res 2019;8. Doi: 10.12688\/f1000research.19144.1.","DOI":"10.12688\/f1000research.19144.1"},{"key":"10.1016\/j.intimp.2024.113883_b0315","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1080\/1744666X.2023.2265567","article-title":"Risankizumab for the treatment of active psoriatic arthritis in adults","volume":"19","author":"Nakamura","year":"2023","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/j.intimp.2024.113883_b0320","doi-asserted-by":"crossref","first-page":"944","DOI":"10.5114\/ada.2022.113405","article-title":"Simulated in vitro hypoxic conditions from psoriatic arthritis cartilage change plasminogen activating system urokinase and serpine functionality. Reversal of antiapoptotic protection suggests common homeostatic buffering","volume":"39","author":"Nohawica","year":"2022","journal-title":"Postepy Dermatol Alergol"},{"key":"10.1016\/j.intimp.2024.113883_b0325","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0065-230X(08)60028-7","article-title":"Plasminogen activators, tissue degradation, and cancer","volume":"44","author":"Dan\u00f8","year":"1985","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.intimp.2024.113883_b0330","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1097\/01.blo0000093845.72468.bd","article-title":"Urokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis","author":"Choong","year":"2003","journal-title":"Clin. Orthop. Relat. Res."},{"key":"10.1016\/j.intimp.2024.113883_b0335","doi-asserted-by":"crossref","unstructured":"Lu P, Takai K, Weaver VM, Werb Z. Extracellular matrix degradation and remodeling in development and disease. Cold Spring Harb Perspect Biol 2011;3. Doi: 10.1101\/cshperspect.a005058.","DOI":"10.1101\/cshperspect.a005058"},{"key":"10.1016\/j.intimp.2024.113883_b0340","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1046\/j.0014-2956.2002.02639.x","article-title":"Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin","volume":"269","author":"Arroyo De Prada","year":"2002","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.intimp.2024.113883_b0345","first-page":"579","article-title":"Examining the functions of the vascular endothelial growth factor\/hypoxia-inducible factor signaling pathway in psoriatic arthritis","volume":"38","author":"Kili\u00e7","year":"2023","journal-title":"ArchRheumatol"},{"key":"10.1016\/j.intimp.2024.113883_b0350","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12969-017-0194-9","article-title":"Joint cartilage thickness and automated determination of bone age and bone health in juvenile idiopathic arthritis","volume":"15","author":"Twilt","year":"2017","journal-title":"Pediatr. Rheumatol. Online J."},{"key":"10.1016\/j.intimp.2024.113883_b0355","doi-asserted-by":"crossref","first-page":"325","DOI":"10.5114\/ceji.2018.80052","article-title":"A fresh look at angiogenesis in juvenile idiopathic arthritis","volume":"43","author":"\u015awidrowska-Jaros","year":"2018","journal-title":"Cent Eur J Immunol"},{"key":"10.1016\/j.intimp.2024.113883_b0360","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/741457","article-title":"Serum Angiogenesis Markers and Their Correlation with Ultrasound-Detected Synovitis in Juvenile Idiopathic Arthritis","volume":"2015","author":"\u015awidrowska","year":"2015","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.intimp.2024.113883_b0365","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.3899\/jrheum.080782","article-title":"The hypoxic synovial environment regulates expression of vascular endothelial growth factor and osteopontin in juvenile idiopathic arthritis","volume":"36","author":"Bosco","year":"2009","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.intimp.2024.113883_b0370","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.clim.2007.04.014","article-title":"Angiogenesis markers (VEGF, soluble receptor of VEGF and angiopoietin-1) in very early arthritis and their association with inflammation and joint destruction","volume":"124","author":"Clavel","year":"2007","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.intimp.2024.113883_b0375","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1080\/03009740802116224","article-title":"Osteoprotegerin\/RANKL system imbalance in active polyarticular-onset juvenile idiopathic arthritis: a bone damage biomarker?","volume":"37","author":"Spelling","year":"2008","journal-title":"Scand. J. Rheumatol."},{"key":"10.1016\/j.intimp.2024.113883_b0380","doi-asserted-by":"crossref","first-page":"R83","DOI":"10.1186\/ar4525","article-title":"Bone mass and quality in patients with juvenile idiopathic arthritis: longitudinal evaluation of bone-mass determinants by using dual-energy x-ray absorptiometry, peripheral quantitative computed tomography, and quantitative ultrasonography","volume":"16","author":"Stagi","year":"2014","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.intimp.2024.113883_b0385","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.omtn.2020.01.014","article-title":"Downregulation of Hypoxia-Inducible Factor-1\u03b1 by RNA Interference Alleviates the Development of Collagen-Induced Arthritis in Rats","volume":"19","author":"Hu","year":"2020","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.intimp.2024.113883_b0390","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s00228-013-1605-6","article-title":"Putative effects of potentially anti-angiogenic drugs in rheumatic diseases","volume":"70","author":"Maruotti","year":"2014","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.intimp.2024.113883_b0395","doi-asserted-by":"crossref","first-page":"4853","DOI":"10.4049\/jimmunol.171.9.4853","article-title":"Blockade of vascular endothelial growth factor receptor I (VEGF-RI), but not VEGF-RII, suppresses joint destruction in the K\/BxN model of rheumatoid arthritis","volume":"171","author":"De Bandt","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2024.113883_b0400","first-page":"1014","article-title":"Drug evaluation: apratastat, a novel TACE\/MMP inhibitor for rheumatoid arthritis","volume":"7","author":"Thabet","year":"2006","journal-title":"Curr. Opin. Invest. Drugs"},{"key":"10.1016\/j.intimp.2024.113883_b0405","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.rmed.2019.08.003","article-title":"VEGF and FGF-2: Promising targets for the treatment of respiratory disorders","volume":"156","author":"Laddha","year":"2019","journal-title":"Respir. Med."},{"key":"10.1016\/j.intimp.2024.113883_b0410","article-title":"Hypoxia-inducible factor 1-alpha is a driving mechanism linking chronic obstructive pulmonary disease to lung cancer","volume":"12","author":"Xu","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.intimp.2024.113883_b0415","first-page":"6077","article-title":"HIF-1\u03b1 promotes inflammatory response of chronic obstructive pulmonary disease by activating EGFR\/PI3K\/AKT pathway","volume":"22","author":"Zhang","year":"2018","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.intimp.2024.113883_b0420","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.2147\/COPD.S177034","article-title":"Correlation of serum levels of HIF-1\u03b1 and IL-19 with the disease progression of COPD: a retrospective study","volume":"13","author":"Rong","year":"2018","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"10.1016\/j.intimp.2024.113883_b0425","first-page":"4553","article-title":"Role of the HIF-1 signaling pathway in chronic obstructive pulmonary disease","volume":"16","author":"Fu","year":"2018","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.intimp.2024.113883_b0430","doi-asserted-by":"crossref","first-page":"377","DOI":"10.2165\/11318860-000000000-00000","article-title":"Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies","volume":"23","author":"Papaetis","year":"2009","journal-title":"BioDrugs"},{"key":"10.1016\/j.intimp.2024.113883_b0435","doi-asserted-by":"crossref","first-page":"41202","DOI":"10.1038\/srep41202","article-title":"The Role of Vascular Endothelial Growth Factor in Small-airway Remodelling in a Rat Model of Chronic Obstructive Pulmonary Disease","volume":"7","author":"Wang","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2024.113883_b0440","doi-asserted-by":"crossref","first-page":"19579","DOI":"10.1073\/pnas.0809763105","article-title":"Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth","volume":"105","author":"Zhang","year":"2008","journal-title":"PNAS"},{"key":"10.1016\/j.intimp.2024.113883_b0445","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1045997","article-title":"Hypoxia inducible factor prolyl hydroxylases in inflammatory bowel disease","volume":"14","author":"Lun","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.intimp.2024.113883_b0450","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1093\/ecco-jcc\/jjac092","article-title":"Hypoxia-Inducible Factor 1-Alpha Stabilizers in the Treatment of Inflammatory Bowel Diseases: Oxygen as a Novel IBD Therapy?","volume":"16","author":"Bhat","year":"2022","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.intimp.2024.113883_b0455","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1136\/ard-2023-224491","article-title":"Expression of HIF1\u03b1 in intestinal epithelium restricts arthritis inflammation by inhibiting RIPK3-induced cell death machinery","volume":"83","author":"Lyu","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2024.113883_b0460","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1172\/JCI200421086","article-title":"Epithelial hypoxia-inducible factor-1 is protective in murine experimental colitis","volume":"114","author":"Karhausen","year":"2004","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.intimp.2024.113883_b0465","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1053\/j.gastro.2010.06.068","article-title":"Loss of prolyl hydroxylase-1 protects against colitis through reduced epithelial cell apoptosis and increased barrier function","volume":"139","author":"Tambuwala","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.intimp.2024.113883_b0470","doi-asserted-by":"crossref","DOI":"10.1038\/s41423-024-01233-y","article-title":"Metabolic rewiring controlled by HIF-1\u03b1 tunes IgA-producing B-cell differentiation and intestinal inflammation","author":"Meng","year":"2024","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.intimp.2024.113883_b0475","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/apt.16753","article-title":"Randomised clinical trial: a phase 1b study of GB004, an oral HIF-1\u03b1 stabiliser, for treatment of ulcerative colitis","volume":"55","author":"Danese","year":"2022","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.intimp.2024.113883_b0480","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/MIB.0000000000000277","article-title":"Oral delivery of prolyl hydroxylase inhibitor: AKB-4924 promotes localized mucosal healing in a mouse model of colitis","volume":"21","author":"Marks","year":"2015","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.intimp.2024.113883_b0485","doi-asserted-by":"crossref","first-page":"41","DOI":"10.15586\/jkcvhl.v9i3.245","article-title":"Understanding the Impact of Belzutifan on Treatment Strategies for Patients with VHL","volume":"9","author":"Arevalo","year":"2022","journal-title":"J Kidney Cancer VHL"},{"key":"10.1016\/j.intimp.2024.113883_b0490","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1007\/s40265-021-01606-x","article-title":"Belzutifan: First Approval","volume":"81","author":"Deeks","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.intimp.2024.113883_b0495","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1016\/j.febslet.2012.04.032","article-title":"Systemic VHL gene functions and the VHL disease","volume":"586","author":"Bader","year":"2012","journal-title":"FEBS Lett."},{"key":"10.1016\/j.intimp.2024.113883_b0500","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1158\/1078-0432.CCR-19-1459","article-title":"HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma","volume":"26","author":"Courtney","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2024.113883_b0505","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1634\/theoncologist.12-6-713","article-title":"FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced\/metastatic recurrent nonsquamous non-small cell lung cancer","volume":"12","author":"Cohen","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.intimp.2024.113883_b0510","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102017","article-title":"Bevacizumab (Avastin\u00ae) in cancer treatment: A review of 15years of clinical experience and future outlook","volume":"86","author":"Garcia","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.intimp.2024.113883_b0515","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1158\/1078-0432.CCR-07-2020","article-title":"Nonviral nanoscale-based delivery of antisense oligonucleotides targeted to hypoxia-inducible factor 1 alpha enhances the efficacy of chemotherapy in drug-resistant tumor","volume":"14","author":"Wang","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2024.113883_b0520","first-page":"991","article-title":"Insights into the therapeutic potential of hypoxia-inducible factor-1\u03b1 small interfering RNA in malignant melanoma delivered via folate-decorated cationic liposomes","volume":"11","author":"Chen","year":"2016","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.intimp.2024.113883_b0525","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/mt.2008.266","article-title":"Targeting hypoxia-inducible factor-1alpha with Tf-PEI-shRNA complex via transferrin receptor-mediated endocytosis inhibits melanoma growth","volume":"17","author":"Liu","year":"2009","journal-title":"Mol. Ther."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924024056?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924024056?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T16:54:11Z","timestamp":1736614451000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924024056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":105,"alternative-id":["S1567576924024056"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.113883","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Where are we in targeting hypoxia-induced pathways in inflammatory arthritis? Current understanding, insights, and future directions","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.113883","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"113883"}}